Sorgem Evaluation was involved in the valuation of a predictive medicine software in anticipation of its planned commercialization through licensing.
MammoRisk® is the first solution developed by Predilife dedicated to stratified breast cancer screening. This software uses a scoring tool based on discriminating criteria combined with a genetic test. As Predilife states in its press release, ‘ MammoRisk® is being used in the MyPeBS clinical trial, funded by the European Union, to analyse the benefits of stratified screening compared with standard screening. It involves 53,000 European women aged between 40 and 70 who are being followed for four years. The results, expected in early 2028, could lead to new official recommendations for breast cancer screening ‘.
Sorgem Evaluation assisted Predilife in evaluating this predictive medicine solution as part of a strategic review linked to its marketing, following the MyPeBS clinical study.
Sorgem Evaluation provided advice on the royalty rate that could be charged for licensing the software to a third party.